Literature DB >> 22102663

Midazolam as an adjunctive therapy for capture myopathy in Bar-tailed Godwits (Limosa lapponica baueri) with prognostic indicators.

Janelle M Ward1, Brett D Gartrell, Jesse R Conklin, Phil F Battley.   

Abstract

Capture myopathy is a complication of capture and handling in many species of birds and mammals. Muscular necrosis leads to ataxia, paralysis, and pain, whereas metabolic disturbances can result in death. We conducted an opportunistic clinical trial on Bar-tailed Godwits (Limosa lapponica baueri) that developed capture myopathy after a cannon-net capture in New Zealand in October 2008. We assessed the beneficial effects of midazolam, a benzodiazepine with the effects of anxiolysis, muscle relaxation, and sedation, in the adjunctive treatment of capture myopathy. Physical and biochemical parameters were analyzed retrospectively for their potential as indicators for survival until release. Birds (n=16) were treated with subcutaneous fluid therapy, a nonsteroidal anti-inflammatory (meloxicam), gavage feeding, and sling therapy twice daily. The treatment group (n=8) was treated twice daily with intramuscular midazolam injections, 1.5 mg/kg. Surviving godwits were released over 1-9 days, with 6 of 8 treated birds (75%) surviving to release, compared with 3 of 8 controls (38%). Inability to counteract weight loss in captivity was the most significant problem for both groups. Lack of waterproofing and predation were contributing causes of death for at least two godwits after release. Birds treated with midazolam showed subjective benefits including improved tolerance of handling and sling therapy. Clinical parameters (change in body mass, packed cell volume [PCV], plasma creatine kinase [CK], aspartate aminotransferase [AST], total protein, and uric acid [UA] over time) were not statistically different between groups, although peak average values for CK, AST, and UA were lower in the treatment group. Decline in body mass (%), PCV, final plasma UA, and peak plasma CK were the most useful prognostic indicators. Midazolam shows potential as an ancillary treatment for capture myopathy in birds and is worthy of continued study and use.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22102663     DOI: 10.7589/0090-3558-47.4.925

Source DB:  PubMed          Journal:  J Wildl Dis        ISSN: 0090-3558            Impact factor:   1.535


  2 in total

1.  Midazolam sedates Passeriformes for field sampling but affects multiple venous blood analytes.

Authors:  J Jill Heatley; Jennifer Cary; Lyndsey Kingsley; Hughes Beaufrere; Karen E Russell; Gary Voelker
Journal:  Vet Med (Auckl)       Date:  2015-01-16

2.  Sedation of Wild Pyrenean Capercaillie (Tetrao urogallus aquitanicus) Using Intramuscular Midazolam.

Authors:  Olga Nicolás Francisco; Ivan Afonso Jordana; Diego Garcia Ferré; Job Roig Simón; Ana Carolina Ewbank; Antoni Margalida; Irene Sacristán; Kévin Foulché; Emmanuel Ménoni; Carlos Sacristán
Journal:  Animals (Basel)       Date:  2022-07-11       Impact factor: 3.231

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.